… If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention
of CNS metastases from NSCLC. Clin Cancer Res; 18(16); 4406–14. ©2012 AACR. …

… the current study are comparable to those from clinical trials of erlotinib, despite our study
population having a high proportion of patients who are usually excluded from study enrollment…

… In this matched-pair case-control study, we demonstrated that gefitinib and erlotinib appeared
to have similar outcomes in patients with advanced/metastatic or recurrent NSCLC who …

… This study was designed to provide evidence for the combined activity of … mRNA expression
in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. …

… study showed that erlotinib and gefitinib had similar effectiveness but gefitinib had a better
safety profile compared to erlotinib… for NSCLC patients compared to erlotinib. However, further …

… We prospectively studied the activity of vorinostat plus erlotinib in EGFR-mutated NSCLC …
The phase I portion of the study aimed to maintain a continuous full dose of erlotinib 150 mg …

… All of the predefined primary analyses of this study demonstrated statistically … erlotinib.
Secondary analyses of all QOL domains also demonstrated an advantage to patients on erlotinib, …

… To our knowledge, our study is the only phase 3 study to … phase 3 study comparing
bevacizumab–erlotinib with erlotinib alone … The overall survival results from these studies will help …

… basis for the selection of the erlotinib control group in this study of EGFR wild-type NSCLC.
… During the conduct of this study, other trials were reported that used erlotinib as a control …

… Firstly, our study enrolled only Japanese patients, therefore we await the results of other
randomized studies with patients treated with the combination of erlotinib plus bevacizumab in …